← Browse by Condition
Medical Condition

hepatocellular carcinoma non resectable

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma non resectable sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma non resectable Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma non resectable?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for hepatocellular carcinoma non resectable, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hepatocellular carcinoma non resectable?
hepatocellular carcinoma non resectable research spans Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hepatocellular carcinoma non resectable clinical trial?
Eligibility criteria for hepatocellular carcinoma non resectable trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
4
Phase 3
1
Top Sponsors
Second Affiliated Hospital of Guangzhou Medical University 2 trials
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 1 trial
Asan Medical Center 1 trial
Chang Gung Memorial Hospital 1 trial

Recruiting Clinical Trials

NCT06397235 Phase 2
Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Enrollment
130 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT04522544 Phase 2
Recruiting

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Enrollment
55 pts
Location
Germany
Sponsor
Institut für Klinische Krebsfo...
View Trial →
NCT05992220 Phase 2
Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Enrollment
138 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT06133062 Phase 2
Recruiting

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Enrollment
45 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
View Trial →
NCT06492395 Phase 3
Recruiting

Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT

Enrollment
178 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology